DARPA Awarded Contract for Resistant Depression Trial

A new clinical trial tests if one-day robotic therapy can help people with treatment-resistant depression.

Updated on Sept. 30, 2026 in Mental Health

A close-up of a high-tech robotic medical arm with articulated metallic joints in a clinical research laboratory. — DARPA has awarded NRx Defense Systems an $11.18 million contract for a clinical trial testing a one-day robotic treatment for depression. AI Illustration. Upload story photo >

Live Poll

Should federal agencies prioritize funding for rapid, one-day medical treatments for depression?

DARPA has awarded NRx Defense Systems an $11.18 million contract to conduct the SPARC-TMS clinical trial. The study evaluates a single-day treatment protocol for major depressive disorder that could eventually be deployed in military settings.

Why it matters

Current treatments for depression are often difficult to sustain, prompting this research into a one-day intervention. The trial addresses the needs of approximately 8.9 million U.S. adults living with treatment-resistant depression.

The FDA-approved SPARC-TMS trial (NCT07227103) tests robotic magnetic stimulation combined with the drug NRX-101. The study builds on earlier research into NMDA receptor function and aims to validate the efficacy of a single-day outpatient treatment protocol.

The players

DARPA

The Defense Advanced Research Projects Agency is the branch of the U.S. Department of Defense responsible for developing emerging technologies for military application.

NRx Defense Systems

A subsidiary of NRx Pharmaceuticals focused on developing neuro-therapeutic interventions for military and civilian populations.

McLean Hospital

A major psychiatric teaching hospital affiliated with Harvard Medical School that serves as a clinical trial site for this study.

Arizona State University

A public research university providing academic and clinical resources for the SPARC-TMS trial.

The details

The treatment protocol utilizes robotic neuronavigated transcranial magnetic stimulation to target brain regions with 1mm precision. This is administered alongside NRX-101, a drug that combines d-cycloserine and lurasidone. By modulating NMDA receptor function, the combined approach aims to address depressive symptoms more rapidly than traditional multi-week antidepressant regimens.

September 30, 2026: NRx Defense Systems announced the DARPA contract award.
1987: Prof. Daniel Javitt established the role of NMDA receptors in brain function.

Health Landscape

This development marks a significant transition from traditional, long-term pharmaceutical antidepressant maintenance toward rapid, intervention-based psychiatric care. It sits within a growing clinical pipeline of protocols designed to address treatment-resistant depression through precision technology.

If you or a loved one are managing treatment-resistant depression, this trial highlights an ongoing shift toward precision-based outpatient care. It is worth discussing with your physician whether clinical trials are an appropriate option given your current treatment history and medical profile.

The takeaway

This trial investigates if advanced robotics and pharmaceutical agents can provide relief for patients who have not responded to standard therapy. If you have been struggling with resistant depression, keep track of emerging psychiatric research and consult a specialist about new clinical trial options.